VXRT
(NASDAQ)
1.73
+0.0462  (+2.68%)
Volume (24h): 3.21M Day Range: 1.69 - 1.84
Market Cap: 122.02M 52W Range: 0.2610 - 3.50
Mar-25-20 03:08PM Top Ranked Momentum Stocks to Buy for March 25thZacks
02:28PM S.F. biotech races potential COVID-19 drug toward clinical trialAmerican City Business Journals
Mar-25-20 01:40PM The Zacks Analyst Blog Highlights: Vaxart, Zoom Video Communications, Amazon.com, Clorox and Costco WholesaleZacks
Mar-24-20 12:05PM Here're the 5 Big Winners from the Coronavirus PandemicZacks
Mar-22-20 02:18PM These 15 companies are working on coronavirus treatments or vaccines — here’s where things standMarketWatch
12:19PM 3 Coronavirus Stocks with Over 60% UpsideTipRanks
Mar-21-20 03:12PM These 15 companies are working on coronavirus treatments or vaccines — here’s where things standMarketWatch
Mar-19-20 08:01PM Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
03:55PM Emergent (EBS) to Help Vaxart Develop Coronavirus VaccineZacks
Mar-19-20 02:25PM Top Ranked Momentum Stocks to Buy for March 19thZacks
Mar-18-20 09:49PM Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & MoreZacks
07:32PM These 15 companies are working on coronavirus treatments or vaccines — here’s where things standMarketWatch
Mar-18-20 03:48PM Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine DevelopmentBenzinga
02:20PM COVID-19 vaccine developer takes key step toward coronavirus trial in early summerAmerican City Business Journals
Mar-18-20 11:54AM Vaxart: Emergent to manufacture Vaxart's experimental COVID-19 vaccineMarketWatch
11:36AM The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 UpdatesBenzinga
Mar-18-20 10:31AM VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATEGlobeNewswire
10:30AM EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASEGlobeNewswire
Mar-17-20 01:21PM Top Ranked Momentum Stocks to Buy for March 17thZacks
Mar-04-20 02:16PM 3 Correction-Defying Bets to Buy as Markets Brave CoronavirusZacks
Mar-02-20 01:18PM The Zacks Analyst Blog Highlights: Co-Diagnostics, VAXART, Sprint, Stamps.com and UnitiZacks
Feb-28-20 02:43PM Market in Correction: 5 Stocks Resist Virus Attack in FebruaryZacks
Feb-27-20 08:36PM Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewswire
01:44PM The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and NovavaxZacks
Feb-26-20 02:08PM 4 Healthcare Stocks to Gain as Coronavirus Threat Looms LargeZacks
Feb-25-20 02:10PM Vaxart, Inc. (VXRT) Shares March Higher, Can It Continue?Zacks
Feb-18-20 02:27PM How a small S.F. design-build software firm could help unlock a coronavirus vaccineAmerican City Business Journals
Feb-12-20 02:30PM 3 Coronavirus Stocks to Snap Up NowTipRanks
Feb-10-20 05:00AM Coronavirus sparks hectic trading in search of treatmentFinancial Times
Feb-07-20 10:35PM As coronavirus infections surge, Bay Area offers a possible drug, diagnostic and adviceAmerican City Business Journals
Feb-03-20 04:16PM Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock UpZacks
Jan-31-20 07:08PM Vaxart's stock rockets on heavy volume after initiating coronavirus vaccine development programMarketWatch
01:00PM Vaxart Announces Initiation of Coronavirus Vaccine ProgramGlobeNewswire
Jan-31-20 12:20PM The Wining Sector & Its Top Stocks in Virus-Infected JanuaryZacks
Jan-24-20 10:55PM Life science companies make first moves to attack deadly coronavirusAmerican City Business Journals
Jan-22-20 01:00PM Results from Influenza Challenge Study Published in Lancet Infectious DiseasesGlobeNewswire
Dec-22-19 09:44PM Hedge Funds Have Never Been This Bullish On Vaxart, Inc. (VXRT)Insider Monkey
Nov-12-19 09:45PM Vaxart Announces Third Quarter 2019 Financial Results and Provides Corporate UpdateGlobeNewswire
Nov-06-19 01:00PM Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus DiseaseGlobeNewswire
Oct-28-19 12:00PM Vaxart, Inc. Announces Changes to its Board of DirectorsGlobeNewswire
Oct-04-19 07:54PM Largest Insider Trades of the WeekGuruFocus.com
Oct-01-19 12:00PM Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019GlobeNewswire
Sep-26-19 02:20PM Vaxart Announces Pricing of $8 Million Underwritten Public OfferingGlobeNewswire
Sep-25-19 12:00PM Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b StudyGlobeNewswire
Sep-18-19 05:12PM Do Institutions Own Vaxart, Inc. (NASDAQ:VXRT) Shares?Simply Wall St.
Sep-10-19 08:56AM Endo Files BLA for CCH With the FDA for Cellulite Candidate (Revised)Zacks
Sep-09-19 01:50PM Endo International Files BLA for Label Expansion of XiaflexZacks
Sep-04-19 12:00PM Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceBusiness Wire
Aug-08-19 08:01PM Vaxart Announces Second Quarter 2019 Financial Results and Provides Corporate UpdateBusiness Wire
Jul-17-19 06:12PM Those Who Purchased Vaxart (NASDAQ:VXRT) Shares A Year Ago Have A 77% Loss To Show For ItSimply Wall St.
Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)